ENDRA Life Sciences Installs First TAEUS System in the UK
February 27 2024 - 8:00AM
Business Wire
King's College Hospital in London Leads UK
Introduction of ENDRA Liver System
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that it has
installed a TAEUS liver system at King's College Hospital NHS
Foundation Trust (KCH) in London, one of the leading centers of
excellence in the United Kingdom's National Health Service
(NHS).
KCH will use ENDRA's TAEUS liver system in a clinical study to
compare its liver fat assessment accuracy with MRI, the
acknowledged research standard. This study is expected to include
approximately 75 subjects, and is intended to provide essential
data to evaluate the TAEUS technology's performance. In addition,
the findings of the study are expected to be submitted for
publication in a peer-reviewed medical journal.
“We’re proud to launch our partnership with one of the United
Kingdom's most highly regarded and influential NHS institutions.
This collaboration not only will strengthen ENDRA's growing
portfolio of clinical evidence, but also potentially marks a
strategic step into the UK’s extensive NHS network. This
partnership with KCH underscores ENDRA’s commitment to enhancing
healthcare delivery and aligns perfectly with the NHS' mission to
provide comprehensive healthcare services to all," stated Francois
Michelon, Chairman and Chief Executive Officer of ENDRA.
"We're looking forward to working with ENDRA and the TAEUS
technology," stated Dr. Ashley Barnabas, Hepatologist in the Liver
Unit at King’s College Hospital NHS Foundation Trust. “The NHS
operates more than 900 hospitals, serves 1.3 million people daily
and is increasingly focusing on liver health. This includes
innovative mobile NHS units that provide liver health assessments
in high-risk communities. ENDRA's versatile TAEUS system could
potentially be suited for such outreach initiatives in the
future."
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology, which
characterizes tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
over 700,000 ultrasound systems in use globally today. TAEUS® is
initially focused on the measurement of fat in the liver as a means
to assess and monitor Steatotic Liver Disease (SLD) (formerly known
as NAFLD-NASH), a chronic liver spectrum that affects over two
billion people globally, and for which there are no practical
diagnostic tools. Beyond the liver, ENDRA is exploring several
other clinical applications of TAEUS®, including tissue temperature
imaging during energy-based surgical procedures. For information,
please visit www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are “forward-looking statements” within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” “anticipate,” “attempt,” “believe,”
“could,” “estimate,” “expect,” “forecast,” “future,” “goal,”
“hope,” “intend,” “may,” “plan,” “possible,” “potential,”
“project,” “seek,” “should,” “will,” “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
estimates of the timing of future events and anticipated results of
its development efforts, including the timing of submission for and
receipt of required regulatory approvals and product launches and
sales; statements relating to future financial position and
projected costs and revenue; expectations concerning ENDRA’s
business strategy; and statements regarding ENDRA’s ability to find
and maintain development partners. Forward-looking statements
involve inherent risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking
statements as a result of various factors including, among others:
the ability to raise additional capital in order to continue as a
going concern; the ability to obtain regulatory approvals necessary
to sell ENDRA medical devices in certain markets in a timely
manner, or at all; the ability to develop a commercially feasible
technology and its dependence on third parties to design and
manufacture its products; ENDRA’s ability to maintain compliance
with Nasdaq listing standards; ENDRA’s dependence on its senior
management team; the ability to find and maintain development
partners; market acceptance of ENDRA’s technology and the amount
and nature of competition in its industry; ENDRA’s ability to
protect its intellectual property; and the other risks and
uncertainties described in the Risk Factors and Management’s
Discussion and Analysis of Financial Condition and Results of
Operations sections of the Company’s most recent Annual Report on
Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed
with the SEC. You should not rely upon forward-looking statements
as predictions of future events. The forward-looking statements
made in this press release speak only as of the date of issuance,
and ENDRA assumes no obligation to update any such forward-looking
statements to reflect actual results or changes in expectations,
except as otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227291943/en/
Company: Irina Pestrikova Senior Director, Finance
investors@endrainc.com www.endrainc.com
Investor Relations: Yvonne Briggs LHA Investor Relations
(310) 691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Jul 2024 to Aug 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Aug 2023 to Aug 2024